Furthermore, inhibiting DYRK1B kinase activity using AZ191 affects FOXO1 stabilization on chromatin, improving hyperglycemia in diabetic mice, highlighting the therapeutic potential of AZ191 in diabetes treatment (Fig. 6F). Here, FOXO1 is linked to Hyperglycemia.